D. Boral Capital downgraded Quince Therapeutics (QNCX) to Hold from Buy without a price target after the company reported negative results from its pivotal Phase 3 NEAT clinical trial in ataxia-telangiectasia. The company’s core value driver has been removed, and the equity “appears fully impaired at this stage,” the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNCX:
- Citizens downgrades Quince Therapeutics on study failure
- Quince Therapeutics downgraded to Market Perform from Outperform at Citizens
- Quince Therapeutics down 88% after reopening for trading
- Quince Therapeutics trading resumes
- Quince down 14% after NEAT study endpoint did not reach statistical significance